Literature DB >> 11505394

Prognostic significance of thymidylate synthase activity in bladder carcinoma.

Y Mizutani1, H Wada, O Ogawa, O Yoshida, M Fukushima, N Nonomura, T Miki.   

Abstract

BACKGROUND: 5-fluorouracil (5-FU) is an anticancer agent clinically used against various cancers including bladder carcinoma. 5-FU inhibits thymidylate synthase (TS) and blocks DNA synthesis. TS is the key enzyme in the catalysis of the methylation from deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate. Little is known about the significance of TS in bladder carcinoma. The authors investigated the activity of TS in 82 bladder cancers and prognostic significance of the levels of TS and/or activities of dihydropyrimidine dehydrogenase (DPD), an important enzyme in the degradation of 5-FU.
METHODS: The levels of TS and DPD activities in nonfixed, fresh, frozen, bladder carcinoma and normal bladder specimens were determined biochemically by the FdUMP binding assay and the 5-FU degradation assay, respectively.
RESULTS: The activity of TS was 10-fold higher in bladder carcinoma compared with normal bladder. TS activity in muscle-invasive bladder carcinoma was threefold higher than that in Ta and T1 cancer. In addition, the activity of TS in T1 bladder carcinoma was threefold higher than that in Ta cancer. The level of TS activity in Grade 3 bladder carcinoma was 4.5-fold and 3.5-fold higher than that in Grade 1 and Grade 2 cancers, respectively. Patients with Ta and T1 bladder carcinoma with low TS activity had a longer postoperative tumor-free period than those with high activity in the 2-year follow-up. Patients with Ta and T1 bladder carcinoma with high or low TS activity were divided into four subgroups: high or low DPD activity subgroups. Patients with low TS activity and high DPD activity had the longest postoperative disease-free period among the 4 subgroups during the 2-year follow-up.
CONCLUSIONS: To the authors' knowledge, the current study is the first study that demonstrated that the level of TS activity correlates with both the progression of the stage and the increase of the grade of bladder carcinoma and that elevated TS activity predicts early recurrence in Ta and T1 bladder carcinoma. These results suggested that elevated TS activity might have been associated with a higher chance of progression and recurrence of bladder carcinoma in the patients who participated in this study. Copyright 2001 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11505394     DOI: 10.1002/1097-0142(20010801)92:3<510::aid-cncr1349>3.0.co;2-0

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  5 in total

1.  Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells.

Authors:  Dimitrios J Stravopodis; Panagiotis K Karkoulis; Eumorphia G Konstantakou; Sophia Melachroinou; Angeliki Thanasopoulou; Gerasimos Aravantinos; Lukas H Margaritis; Ema Anastasiadou; Gerassimos E Voutsinas
Journal:  J Cancer Res Clin Oncol       Date:  2010-04-28       Impact factor: 4.553

2.  Relationship between the expression of thymidylate synthase, thymidine phosphorylase and dihydropyrimidine dehydrogenase and survival in epithelial ovarian cancer.

Authors:  Changyu Wang; Yanjie Weng; Hongyan Wang; Ying Shi; Ding Ma
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-08-17

3.  Prognostic significance of 5-fluorouracil metabolism-relating enzymes and enhanced chemosensitivity to 5-fluorouracil by 5-chloro 2,4-dihydroxy-pyridine in urothelial carcinoma.

Authors:  Hiroki Ide; Eiji Kikuchi; Masanori Hasegawa; Norihide Kozakai; Takeo Kosaka; Akira Miyajima; Mototsugu Oya
Journal:  BMC Cancer       Date:  2012-09-22       Impact factor: 4.430

4.  Expression of thymidylate synthase in human cells is an early G(1) event regulated by CDK4 and p16INK4A but not E2F.

Authors:  B G Le François; J A Maroun; H C Birnboim
Journal:  Br J Cancer       Date:  2007-10-09       Impact factor: 7.640

5.  Expression level of dihydropyrimidine dehydrogenase is associated with clinical outcome in patients with T1G3 bladder cancer treated with Bacillus Calmette-Guerin.

Authors:  Hiroki Ide; Eiji Kikuchi; Shuji Mikami; Akira Miyajima; Mototsugu Oya
Journal:  BMC Res Notes       Date:  2014-09-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.